Home » Newsletters » BioWorld Science

BioWorld Science

July 21, 2015

View Archived Issues

Aerosolized Ebola vaccine shows promising protective effect in nonhuman primates

Panther Biotechnology completes acquisition of Faulk Pharmaceuticals assets

Glypican-1 identified as potential diagnostic marker for pancreatic cancer

Heron Therapeutics resubmits Sustol NDA in U.S. for CINV

Cellceutix's brilacidin to advance to phase III for ABSSSI

Agenus acquires antibodies targeting CEACAM1

ASLAN and National Cancer Centre Singapore sign MOU to collaborate in gastric cancer

Fibrocell and Intrexon confirm IND filing of FCX-007 for recessive dystrophic epidermolysis bullosa

MGB Biopharma initiates phase I trial of MGB-BP-3 for C. difficile infections

Purdue Pharma patents morphinan analogs

Nanjing Sanhome Pharmaceutical discloses anti-HCV agents

Gilead introduces SYK inhibitors

Cadila divulges FFAR1 agonists

Bristol-Myers patents BRD4 inhibitors

BioMarin updates on development of talazoparib in breast cancer

Exelixis reports topline results from phase III trial of cabozantinib in renal cell carcinoma

DSMB recommends continuation of Graspa pancreatic cancer trial

Biotie starts phase III trial of tozadenant in Parkinson's disease

Nivolumab BMS approved in E.U. for squamous NSCLC

Novonco licenses rights to COH-29 from City of Hope

Purdue Pharma reports Nav1.7 channel blockers

Valeant agrees to acquire leading Egyptian pharmaceutical company

Virginia Commonwealth University patents NO-releasing allosteric Hb modifiers

SUVN-G3031 demonstrates procognitive effects without affecting sleep

TRV-101 reduces beta-amyloid and tau toxic aggregates in animal models of AD

CheckMate-025 study of Opdivo stopped early after meeting endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...